Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4

被引:2
|
作者
Jiang, Pin [1 ]
Chen, Tao [2 ]
Chu, Lin-Feng [1 ]
Xu, Ren-Peng [1 ]
Gao, Jin-Ting [3 ]
Wang, Li [3 ]
Liu, Qiang [3 ]
Tang, Lily [3 ]
Wan, Hong [1 ]
Li, Ming [4 ]
Ren, Hong-Can [3 ]
机构
[1] Shanghai Medicilon Inc, Dept DMPK, 585 Chuanda Rd, Shanghai 201299, Peoples R China
[2] Shanghai PharmoGo Co Ltd, Shanghai, Peoples R China
[3] GenFleet Therapeut Shanghai Inc, Drug Discovery Dept, 1206 Zhangjiang Rd, Suite A, Shanghai 201203, Peoples R China
[4] Zhengzhou Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, 1 Jianshe Rd, Zhengzhou 450000, Peoples R China
关键词
Drug-drug interaction; PBPK; fraction metabolized; CYP inhibition;
D O I
10.1080/17425255.2023.2263358
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Enhancing the precision of drug-drug interaction (DDI) prediction is essential for improving drug safety and efficacy. The aim is to identify the most effective fraction metabolized by CY3A4 (fm) for improving DDI prediction using physiologically based pharmacokinetic (PBPK) models.Research Design and Methods: The fm values were determined for 33 approved drugs using a human liver microsome for in vitro measurements and the ADMET Predictor software for in silico predictions. Subsequently, these fm values were integrated into PBPK models using the GastroPlus platform. The PBPK models, combined with a ketoconazole model, were utilized to predict AUCR (AUCcombo with ketoconazole/AUCdosing alone), and the accuracy of these predictions was evaluated by comparison with observed AUCR.Results: The integration of in vitro fm method demonstrates superior performance compared to the in silico fm method and fm of 100% method. Under the Guest-limits criteria, the integration of in vitro fm achieves an accuracy of 76%, while the in silico fm and fm of 100% methods achieve accuracies of 67% and 58%, respectively.Conclusions: Our study highlights the importance of in vitro fm data to improve the accuracy of predicting DDIs and demonstrates the promising potential of in silico fm in predicting DDIs.
引用
收藏
页码:721 / 731
页数:11
相关论文
共 50 条
  • [11] Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors
    Chen, Grace
    Sun, Kefeng
    Michon, Ingrid
    Barter, Zoe
    Neuhoff, Sibylle
    Ghosh, Lipika
    Ilic, Katarina
    Song, Ivy H.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (05): : 590 - 600
  • [12] Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone
    Wendl, Thomas
    Frechen, Sebastian
    Gerisch, Michael
    Heinig, Roland
    Eissing, Thomas
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (02): : 199 - 211
  • [13] Physiologically-Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug-Drug Interactions
    Sahasrabudhe, Siddhee A.
    Cheng, Shen
    Al-Kofahi, Mahmoud
    Jarnes, Jeanine R.
    Weinreb, Neal J.
    Kartha, Reena, V
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1254 - 1263
  • [14] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ZAVEGEPANT
    Ke, A.
    Callegari, E.
    Bhardwaj, R.
    Varma, M.
    Muto, C.
    Bertz, R.
    Sahasrabudhe, V.
    Liu, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S107 - S107
  • [15] In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin
    Mamidi, Rao N. V. S.
    Dallas, Shannon
    Sensenhauser, Carlo
    Lim, Heng Keang
    Scheers, Ellen
    Verboven, Peter
    Cuyckens, Filip
    Leclercq, Laurent
    Evans, David C.
    Kelley, Michael F.
    Johnson, Mark D.
    Snoeys, Jan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (05) : 1082 - 1096
  • [16] Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants
    Salerno, Sara N.
    Edginton, Andrea
    Gerhart, Jacqueline G.
    Laughon, Matthew M.
    Ambalavanan, Namasivayam
    Sokol, Gregory M.
    Hornik, Chi D.
    Stewart, Dan
    Mills, Mary
    Martz, Karen
    Gonzalez, Daniel
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (01) : 253 - 262
  • [17] PREDICTION OF DRUG-DRUG INTERACTIONS (DDI) WITH A MODERATE CYP3A INDUCER: DEVELOPMENT AND VALIDATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL OF RIFABUTIN
    Sorour, M.
    Mundra, V.
    Zhang, H.
    Sahasranaman, S.
    Ou, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S75 - S75
  • [18] Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies
    Ou, Ying
    Xu, Yang
    Gore, Lia
    Harvey, R. Donald
    Mita, Alain
    Papadopoulos, Kyriakos P.
    Wang, Zhengping
    Cutler, Richard E.
    Pinchasik, Dawn E.
    Tsimberidou, Apostolia M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (03) : 530 - 539
  • [19] APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO BOSUTINIB PHARMACOKINETICS: PREDICTION OF DRUG-DRUG INTERACTIONS AS CYP3A SUBSTRATE.
    Ono, C.
    Hsyu, P.
    Abbas, R.
    Loi, C.
    Yamazaki, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S74 - S74
  • [20] A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4
    Templeton, Ian
    Ravenstijn, Paulien
    Sensenhauser, Carlo
    Snoeys, Jan
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2016, 37 (01) : 15 - 27